Core B: Probe and Pharmaceutical Optimization

The role of Core B, the Probe and Pharmaceutical Optimization Core, is to promote the overall Center goal by providing general medicinal chemistry, formulation and pharmacology support. Core B will function as an integral component of the Center by supporting Projects 1, 2 and 3, and by closely collaborating with Core A, the Analytical Chemistry Core. Core B will synthesize the chemical threat agent tetramethylenedisulfotetramine (TETS) and specific mechanistic probes for the individual projects, including TETS-haptens and analogs for the development of a TETS detection assay in Core A. Core B will further use its medicinal chemistry expertise to synthesize and characterize potential novel therapeutics, including soluble epoxide hydrolase (sEH) inhibitors, dual sEH/cyclooxygenase-2 (COX-2) or sEH/phosphodiesterase inhibitors, activators of small-conductance calcium-activated potassium channels (KCa2), blockers of the microglial voltage-gated potassium channel Kv1.3, as well as AMPA, ryanodine or GABA receptor antagonists, as required by the projects. Having a core dedicated to probe and reagent design, synthesis and/or verification will help ensure consistency, efficacy and reproducibility across the projects of the UC Davis Center and the CounterACT program. In contrast to the first project period, where the emphasis was on delivering libraries of diverse compounds for in vitro screening, the emphasis now will be on optimizing previously identified leads and candidate therapeutics for bioavailability, half-life and central nervous system (CNS) penetration. Core B will further devote significant effort to performing rapid efficacy and safety screens of candidate therapeutics and therapeutic combinations to help inform compound-combinations and dose-selection for Projects 2 and 3.

Related Publications

Atefeh Mousavi Nik, Brandon Pressly, Vikrant Singh, Shane Antrobus, Susan Hulsizer, Michael A. Rogawski, Heike Wulff and Isaac N. Pessah
Molecular Pharmacology April 20, 2017, mol.117.108563; DOI:
Hai M. Nguyen, Vikrant Singh, Brandon Pressly, David Paul Jenkins, Heike Wulff and Vladimir Yarov-Yarovoy
Molecular Pharmacology January 26, 2017, mol.116.108068; DOI:
Vito ST, Banks CN, Inceoglu B, Bruun DA, Zolkowska D, McCoy MR, Rogawski MA, Hammock BD, Lein PJ
Toxicol Appl Pharmacol (in press)
Coleman N, Brown BM, Oliván-Viguera A, Singh V, Olmstead MM, Valero MS, Köhler R, Wulff H
Mol Pharmacol. 2014 Sep;86(3):342-57. doi: 10.1124/mol.114.093286
PubMed PMID: 
PubMed PMCID: 
Zolkowska D1, Banks CN, Dhir A, Inceoglu B, Sanborn JR, McCoy MR, Bruun DA, Hammock BD, Lein PJ, Rogawski MA
J Pharmacol Exp Ther. 2012 May;341(2):435-46. doi: 10.1124/jpet.111.190579. Epub 2012 Feb 10.
PubMed PMID: